PCSA

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.